GLP-1 Medications May Work Effectively with Less Frequent Dosing
New research suggests GLP-1 drugs could maintain benefits with reduced dosing frequency, potentially improving convenience and adherence.
20 articles
New research suggests GLP-1 drugs could maintain benefits with reduced dosing frequency, potentially improving convenience and adherence.
Learn what glucose and ketones in your urine actually mean for your metabolic health and diabetes risk.
New biomarker combining inflammation and glucose metabolism predicts stroke risk better than single measurements in middle-aged adults.
A landmark review maps how computational heart models can decode diabetic cardiomyopathy and predict responses to SGLT2i and GLP-1 drugs.
New evidence suggests oral semaglutide sustains long-term improvements in key CVD risk factors, expanding its role beyond diabetes management.
Chinese study of 4,157 adults finds cumulative CTI index outperforms single measurements for cardiovascular risk prediction.
CTI index combining inflammation and insulin resistance shows 111% higher death risk in 5,847 Chinese adults.
New analysis reveals oral semaglutide significantly reduces cardiovascular risk factors beyond blood sugar control in type 2 diabetes.
Safety alert reveals preventable deaths from medication mismanagement in hospitals treating diabetes patients.
Wearable devices enable continuous cardiovascular monitoring, empowering patients and providing clinicians with real-world health data.
New JAMA patient guide simplifies type 2 diabetes symptoms, diagnosis, and treatment options for better health outcomes.
New research challenges conventional wisdom about optimal blood pressure targets for diabetic patients and cardiovascular outcomes.
New research reveals how dopamine antagonists could prevent dangerous hypoglycemia unawareness in diabetic patients.
New oral formulations of popular GLP-1 medications may eliminate the need for weekly injections while maintaining benefits.
Dr. Jamnadas explains why meal timing matters more than calories for reversing insulin resistance and lowering blood pressure naturally.
New research reveals GLP-1 receptor agonists could significantly reduce cardiovascular risk in broader patient populations.
Comprehensive review exposes gaps in diabetic neuropathy treatment and identifies promising new therapeutic targets beyond glucose management.
New biomarker soluble endoglin shows promise for early detection of cardiovascular and metabolic disorders in blood tests.
Health authorities issue new warnings as reports of fatal pancreatitis cases increase among GLP-1 drug users.
A new framework combining rapid point-of-care fibrinogen testing, viscoelastic assays, and lab tests could eliminate preventable postpartum deaths.